Last mentioned: Mar 10, 2026
Clinical Milestones
Anticipated updates on Phase 1/2 glioblastoma trial progress.
BioFlorida Showcase
Cornerstone Session presentation on Innovation in South Florida.
Investival Showcase
Presentation at the South Florida Rising Life Science Hub event.
National Engagement
Presented at BioCom California and BIO Investor Forum to engage global partners.
Myosin Therapeutics has been selected to present its novel nanomotor-dependency platform at two major South Florida life sciences conferences this March. The company is advancing MT-125, a first-in-class inhibitor currently in Phase 1/2 trials for glioblastoma, as it seeks to capitalize on South Florida's emergence as a biotechnology hub.
This page surfaces every story mentioning MT-125 across our startup coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running startup beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where MT-125 was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |